Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium-Reference-Cited by-同舟云学术

Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium

Published:2014-11-21 Issue:3 Volume:24 Page:340-354
ISSN:0961-5423
Container-title:European Journal of Cancer Care
language:en
Short-container-title:Eur J Cancer Care (Engl)

Author:

Frederix G.W.J.¹,Severens J.L.²,Hövels A.M.¹,van Hasselt J.G.C.³,Hooiveld M.J.J.⁴,Neven P.⁵,Raaijmakers J.A.M.¹,Schellens J.H.M.¹⁶⁷

Affiliation:

1. Science Faculty; Department of Pharmaceutical Sciences; Utrecht University; Utrecht the Netherlands

2. Department of Health Policy and Management; Erasmus University Rotterdam; Rotterdam the Netherlands

3. Faculty of Science; Leiden Academic Centre for Drug Research; Leiden the Netherlands

4. Vertex Pharmaceuticals; Haarlem the Netherlands

5. Multidisciplinary Breast Centre; UZ Leuven; Leuven Belgium

6. Departments of Clinical Pharmacology and Molecular Pathology; The Netherlands Cancer Institute; Amsterdam the Netherlands

7. Department of Pharmacy and Pharmacology; Slotervaart Hospital/Netherlands Cancer Institute; Amsterdam the Netherlands

Publisher

Wiley

Subject

Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ecc.12266/fullpdf

Reference36 articles.

1. Estimating medical costs with censored data;Bang;Biometrika,2000

2. Beleidsregel ziekenhuiszorg 2012 http://www.nza.nl/regelgeving/beleidsregels/ziekenhuiszorg/BR-CU-2065

3. Belgisch Centrum voor Farmacotherapeutische informatie 2012 http://www.bcfi.be/

4. [Advanced breast cancer: an evaluation of the cost of recurrence];Bercez;Bulletin Du Cancer,1999

5. Metastatic breast cancer: we do need primary cost data;Bonastre;Breast,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data;Health Economics Review;2021-09-10

2. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands;Value in Health;2021-05

3. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age;Advances in Therapy;2020-03-14

4. Changing costs of metastatic non small cell lung cancer in the Netherlands;Lung Cancer;2017-12

5. Measuring the costs of cancer treatment - what model should we use?;European Journal of Cancer Care;2015-04-15